<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002157</url>
  </required_header>
  <id_info>
    <org_study_id>MEC09-2-075</org_study_id>
    <secondary_id>NL27372.068.09</secondary_id>
    <nct_id>NCT01002157</nct_id>
  </id_info>
  <brief_title>The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification</brief_title>
  <acronym>VitaK-CAC</acronym>
  <official_title>The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VitaK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both Coronary Artery Calcification (CAC)and its annual progression are a strong predictors of&#xD;
      cardiovascular events. The development of arterial calcification results from imbalance&#xD;
      between calcification promoting and inhibiting factors. An important inhibitor of&#xD;
      calcification is Matrix Gla Protein (MGP): a protein present in the vascular wall where it is&#xD;
      synthesized by Vascular Smooth Muscle Cells (VSMC). MGP requires Vitamin K-mediated&#xD;
      carboxylation to function properly. Deficiency of Vitamin K has been demonstrated to cause&#xD;
      arterial calcification and a diet containing large amounts of Vitamin K2 was associated with&#xD;
      lower CAC and cardiovascular risk. In animal studies, active supplementation of Vitamin K2&#xD;
      caused regression of existing arterial calcification. Therefore, the aim of this randomized,&#xD;
      double-blind, placebo-controlled clinical trial is to investigate whether daily&#xD;
      supplementation of Vitamin K2 (Menaquinone-7) to patients with established CAC will lead to a&#xD;
      decreased progression-rate of CAC after 24 months of follow-up in comparison to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Calcification-score progression</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness measured by Carotid-Femoral Pulse-Wave Velocity</measure>
    <time_frame>0, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Intima Media Thickness</measure>
    <time_frame>0, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin K2 supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Menaquinone-7 (Vitamin K2)</intervention_name>
    <description>Menaquinone-7 (Vitamin K2)</description>
    <arm_group_label>Vitamin K2 supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Capsules containing no Menaquinone-7</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Baseline Coronary Computed Tomographic Angiography (CCTA) of sufficient quality&#xD;
&#xD;
          -  Baseline Agatston calciumscore 100 - 400&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline-scan of insufficient quality&#xD;
&#xD;
          -  Heart rate greater than 70 beats per minute during first scan.(despite adequate&#xD;
             treatment with metoprolol)&#xD;
&#xD;
          -  Chronic or paroxysmal Atrial Fibrillation&#xD;
&#xD;
          -  Presence or scheduled coronary revascularization procedure&#xD;
&#xD;
          -  History of myocardial infarction or stroke.&#xD;
&#xD;
          -  Presence of Diabetes Mellitus.&#xD;
&#xD;
          -  Known kidney disease or a Glomerular Filtration Rate (GFR)MDRD &lt; 60 ml/min/1.73m2&#xD;
&#xD;
          -  Malignant disease (exception: treated basal-cell or squamous cell carcinoma).&#xD;
&#xD;
          -  Use of Vitamin K antagonists.&#xD;
&#xD;
          -  A life-expectancy &lt; 2 years&#xD;
&#xD;
          -  Pregnancy or wish to become pregnant in the near future.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abraham Kroon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter de Leeuw, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Calcification</keyword>
  <keyword>Vitamin K</keyword>
  <keyword>Trial</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

